Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Amgen (NASDAQ:AMGN) by 382.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,389,775 shares of the medical research company’s stock after purchasing an additional 1,101,649 shares during the period. Amundi Pioneer Asset Management Inc. owned about 0.19% of Amgen worth $241,682,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the company. Janus Henderson Group PLC grew its stake in Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the period. FMR LLC grew its stake in Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the period. Renaissance Technologies LLC grew its stake in Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the period. Nordea Investment Management AB grew its stake in Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the period. Finally, Parametric Portfolio Associates LLC grew its stake in Amgen by 51.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 2,299,191 shares of the medical research company’s stock worth $395,990,000 after acquiring an additional 784,957 shares during the period. 79.54% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Friday, March 16th. The shares were sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 4,575 shares of company stock worth $818,330 in the last 90 days. Company insiders own 0.19% of the company’s stock.
NASDAQ:AMGN opened at $171.38 on Tuesday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The firm has a market cap of $114,595.02, a P/E ratio of 13.62, a price-to-earnings-growth ratio of 2.10 and a beta of 1.36. Amgen has a twelve month low of $152.16 and a twelve month high of $201.23.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.89 EPS. sell-side analysts forecast that Amgen will post 13.26 EPS for the current year.
Amgen declared that its Board of Directors has approved a share repurchase program on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 3.08%. Amgen’s payout ratio is 41.97%.
AMGN has been the subject of several recent analyst reports. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and lifted their target price for the stock from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Citigroup lowered shares of Amgen to a “neutral” rating in a report on Monday, December 18th. JPMorgan Chase reiterated a “hold” rating and issued a $191.00 price target on shares of Amgen in a report on Sunday, February 4th. Mizuho set a $192.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 price target on the stock. in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus price target of $190.57.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/amundi-pioneer-asset-management-inc-acquires-1101649-shares-of-amgen-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.